Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 P512 | DOI: 10.1530/endoabs.81.P512

1Aalborg University Hospital, Endocrinology, Aalborg, Denmark; 2Steno Diabetes Center, North Jutland, Aalborg, Denmark


Objective: To study time-dependent changes in the prevalence and patient characteristics of acromegaly, as well as to access the impact of changes in treatment on disease control.

Methods: A total of 107 patients with acromegaly were identified by healthcare registries and subsequently validated by patient chart review over a three-decade period (1992-2021).

Results: The prevalence of acromegaly significantly increased throughout the study period (R2 =0.94, P<0.001) and was 122 cases/106 in 2021 whereas the annual incidence was constant 4.6 cases/106. The age at the first sign of acromegaly and the age at diagnosis significantly increased during the study period, whereas GH and IGF-I decreased. Incidentalomas constituted 32% of all cases diagnosed with acromegaly in the last decade. Primary surgery was used in 93% of all cases, and reoperations decreased from 24% to 10% during the three decades. The use of somatostatin analogues (SSA, 21%-48%) and second-line medical treatment (4%-20%) increased with a concomitant improvement of biochemical disease control (58%-91%).

Conclusion: The prevalence of acromegaly is higher than previously reported and the clinical presentation has shifted towards a milder phenotype. Modern treatment of acromegaly enables individualized treatment and disease control in the majority of patients.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.